World Journal of
Pharmaceutical and Life Sciences

COVID 19- HUMAN CORONA VIRUSE

Ritu Kainth* and Harsimran singh

ABSTRACT

Human corona viruses (HCoVs) are known respiratory pathogens associated with a range of respiratory outcomes. In the past 12- 14 years, the onset of severe acute respiratory syndrome corona virus (SARS-CoV) and Middle East respiratory syndrome corona virus (MERS-CoV) have thrust HCoVs into spotlight of the research community due to their high pathogen city in humans. Corona viruses possess a distinctive morphology, the name being derived from the outer fringe, or ?Corona? of embedded envelope protein. Members of the family corona viridae cause a broad spectrum of animal and human diseases. Uniquely, replication of the RNA genome proceeds through the generation of a nested set of viral mRNA molecules. The study of HCoV-host interaction has contributed extensively to our understanding of HCoV pathogenesis. In present time, the pandemic of corona virus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials.

[Full Text Article]   [Download Certificate]